One Kendall Square
Building 1400W, 2nd Floor
128 articles with Quanterix
Quanterix Corporation announced financial results for the three months ended March 31, 2019.
Amol brings global pharmaceutical and diagnostic industry experience to management team to support rapid company growth
Quanterix to Release Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Thursday, March 7, 2019
Quanterix Corporation announced that it will release its financial results for fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019.
Chief Executive Officer will speak at the Leerink Partners Global Healthcare Conference and the Cowen and Company Health Care Conference
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity Medical Technologies & Diagnostic Forum,
Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology
Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products
Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research
85% revenue growth
Quanterix to Release Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 1, 2018
Quanterix Corporation today announced that it will release its financial results for third quarter 2018 after the close of trading on Thursday, November 1, 2018.
Quanterix’ technology to be used in multiplex diagnostic test for cervical disease detection
Quanterix’ Simoa Technology Powers Record Number of Presentations and Poster Sessions at ECTRIMS 2018
International multiple sclerosis conference features 35 new studies using Simoa technology demonstrating potential of Neurofilament light chain (NfL) as a reliable and sensitive disease biomarker
New research marks the latest example of neurofilament light chain (NfL) as a critical biomarker for detecting brain injuries
Top researchers join precision health visionary for an in-depth discussion examining how biomarkers are innovating the drug development process and shortening approval times
Company also attending Citi’s 13th Annual Biotech Conference
66% revenue growth
Neurofilament light chain (NfL) proves to be a transformative biomarker for understanding wide range of neurological conditions and advancing clinical trials
Quanterix Corporation announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity 38th Annual Growth Conference, on Thursday, Aug. 9, 2018 at 10 a.m., EDT at the InterContinental Boston.
Quanterix to Release Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
Quanterix Corporation announced that it will release its financial results for second quarter 2018 after the close of trading on Wednesday, August 8, 2018.
NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.
Quanterix’ Ultra-Sensitive Technology Creates Breakthroughs in Brain Health of Military and Veterans
New research advances the diagnosis of concussions and PTSD for those in the line of duty